US Stock Market Closed

Dashboard

Tricida, Inc. (TCDA)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.

CEO

Gerrit Klaerner

Employees

119

Industry

Urology Biopharmaceuticals

Sector

Healthcare

Headquarters

South San Francisco

Exchange

NASDAQ

Summary Stats

Market Cap

13.7M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 4 analysts

High

$20.00

Average

$13.00

Low

$6.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.11

Actual

-$0.43 +20.4%

Consensus

-0.54

Report Date

Year Ago

-0.61

Year Ago Change %

Up 29%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites